Asymmetry Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Asymmetry Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$6.44M	Buy	43,876 +1,885	+4%	+$293K	3.42%	15
2021 Q3	$7.43M	Sell	41,991 -15,988	-28%	-$2.57M	4.47%	11
2021 Q2	$9.37M	Buy	57,979 +33,716	+139%	+$5.41M	6.44%	5
2021 Q1	$4.16M	Buy	+24,263	New	+$4.8M	2.15%	19
2020 Q1	–	Sell	-6,950	Closed	-$896K	–	38
2019 Q4	$896K	Buy	+6,950	New	+$670K	1.61%	30

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Asymmetry Capital Management's MRTX Position: Q4 2021 in Review

Asymmetry Capital Management increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 4.5% in Q4 2021, buying an estimated $293K and bringing the position to 43,876 shares worth $6.44M. The position accounts for 3.42% of the portfolio, ranked #15.

Asymmetry Capital Management first reported a position in MRTX in Q4 2019 and has held it in 5 quarters since. The position peaked at $9.37M in Q2 2021. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

Asymmetry Capital Management held 43,876 shares of Mirati Therapeutics, Inc. Common Stock worth $6.44M as of Q4 2021.
Asymmetry Capital Management bought 1,885 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $293K.
Mirati Therapeutics, Inc. Common Stock made up 3.42% of Asymmetry Capital Management's portfolio in Q4 2021, its #15 holding.
Asymmetry Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and has held it in 5 quarters since.
Asymmetry Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $9.37M in Q2 2021.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.